Dr. Laleh Amiri-Kordestani, MD
Medical Officer, Division of Oncology Products 1, Food and Drug Administration, Centre for Drug Evaluation and Research, Silver Spring, MD, USA
Laleh Amiri-Kordestani, M.D. is a clinical team leader and cardio-oncology liaison at the FDA, CDER, Office of Hematology and Oncology Products. At the FDA, Dr. Amiri has focused on cardio-oncology and breast cancer oncology drug development. Dr. Amiri attended the University of Tehran Medical Sciences.
Co-Chair: Session 7 - Cardio-Oncology & Heamato-OncologyRead More...
She did a year of post-doctoral research fellowship in Molecular Genetics Laboratory at NIH and went on to study internal medicine at the Georgetown University/Washington Hospital Center and completed her medical oncology and hematology fellowship at the National Cancer Institute (NCI) in Bethesda, MD. In addition, she pursued an M.S. degree in Clinical Research in the Joint Program of the National Cancer Institute and Duke University. Under the direction of Dr. Sandra Swain, she became familiar with the design and implementation of oncology clinical trials and at the NCI she worked with Dr. Susan Bates focusing on early phase clinical trials. Dr. Amiri remains clinically active, treating breast cancer patients at NCI and practicing inpatient medicine at Georgetown University Hospital.
Dr. Ana Barac, MD, PhD, FACC
Staff Cardiologist, MedStar Heart and Vascular Institute; Associate Professor of Medicine and Oncology, Georgetown University, Washington, DC, USA
Ana Barac, MD, PhD, is a staff cardiologist at MedStar Heart and Vascular Institute and an Associate Professor of Medicine and Oncology at Georgetown University. Her clinical and research interests focus on the mechanisms, diagnosis and treatment of cardiovascular disease in patients undergoing cancer treatment and she leads MedStar’s Cardio-Oncology program. Dr. Barac’ clinical expertise is in cardiac magnetic resonance and echocardiography.
Co-Chair: Session 5 - Coordinating Primary Care in Cardio-OncologyRead More...
She previously was a research fellow at the National Institutes of Health and was a recipient of KL2 Scholar Award from the Georgetown-Howard Universities Center for Clinical and Translational Science for investigations of cardiovascular toxicity in patients with breast cancer. Dr. Barac is the current Chair of the American College of Cardiology (ACC) Cardio-Oncology Council and serves on the editorial boards of the Journal of the American College of Cardiology (JACC), Journal of Cardiovascular Translational Research and the Cardio-Oncology journal.
Dr. Anne Blaes, MD, MS
Associate Professor, Division of Hematology, Oncology and Transplantation, Program Director, Adult Cancer Survivor Program, University of Minnesota, Minneapolis, MN, USA
Dr. Anne Blaes is an associate professor in the Division of Hematology, Oncology and Transplantation at the University of Minnesota and a member of the Masonic Cancer Center. She is a graduate from the University of Notre Dame and Loyola University Chicago, Stritch School of Medicine. She completed her residency, chief residency and fellowship, and a masters in clinical research at the University of Minnesota prior to joining the faculty where she has received numerous teaching awards including The Gold Foundation Humanism and Excellence in Teaching Award, an Educational Excellence Award, and an Outstanding Clinical Educator awards.
Conference Topic: Session 3 - Novel pathophysiology of cardiovascular risk with estrogen antagonistsRead More...
She now directs the Adult Cancer Survivor Program at the University of Minnesota. Dr. Blaes has a special interest in cancer survivorship, the late effects of cancer therapy, and medical education. Her research interests, funded by a BIRCWH K12 award, include quality of life, cardiac complications of chemotherapy, and the late effects of cancer therapy in cancer survivors, particularly breast and colorectal cancer survivors. She is a member of the Alliance for Cancer Clinical Trials Health Outcomes committee and the American Society of Cinical Oncology’s Cancer Survivorship Committee.
Prof. Jutta Bergler-Klein, MD, FESC
Professor of Medicine and Cardiology; Head of Cardiac Outpatients and Acute first care unit; Vice Head, Day Clinic; Senior Consultant Cardiology Dept. of Cardiology, University Clinic of Internal Med. II, Medical University of Vienna, AKH General Hospital, Vienna, Austria
At the Medical University of Vienna, Prof. Jutta Bergler-Klein heads the cardiac outpatient clinic. She is currently chair of the Echo Working Group of the Austrian Society of Cardiology and involved in the European EACVI, and fellow of the ESC. Special research interests are valve disease, biomarkers and cardio-oncology.
Conference Topic: Session 4 - How to Treat Radiation-Induced Coronary Disease? Prevention & Treatment
Dr. Daniela Cardinale, MD, PhD
Cardioncology Unit Director, European Institute of Oncology, Milan, Italy
Dr. Daniela Cardinale graduated from the University of Milan in 1987 and specialized in Cardiology (Milan 1992). She holds a PhD in Cardiovascular Physiopathology from the same University (2009). She is currently Director of the Cardioncology Unit of the European Institute of Oncology in Milan, where she has been working since 1994.
Co-Chair: Session 6 - Young Investigator CompetitionRead More...
She has previously worked at the Operative Unit of Intensive Cardiac Care of the Centro Cardiologico Monzino (1987-1990) and at the Cardiology Division of S. Raffaele Hospital of Milan (1990-1994). Her professional experience and investigational interests focus on prevention, early detection, monitoring and treatment of cardiotoxicity; screening of cardiotoxicity in patients with cardiac disease; malignant pericardial effusion evaluation and intrapericardial treatment. Since 2009, she is the Vice-President of the ICOS (International CardiOncology Society). She is a fellow of the European Society of Cardiology.
Dr. John-Paul Carpenter, MBBS, BSc(Hons), FRCP(UK), MD(Res)
Consultant Cardiologist and Clinical Lead for Cardiology, Poole Hospital NHS Foundation Trust, Poole, Dorset, United Kingdom
Dr Carpenter is a Cardiologist and Clinical Lead for Cardiology at Poole Hospital with a specialist interest in cardio-oncology and cardiovascular imaging. He qualified in 1996 from Guy's and St. Thomas' Hospitals before training in Cardiology. He was appointed to a National Institutes of Health (NIH) funded research Fellowship at the Royal Brompton Hospital in London in 2007, followed by a Clinical Fellowship in imaging and heart failure at University Hospitals Southampton before taking up a locum consultant position in cardiovascular MRI, inherited cardiac diseases and cardio-oncology at the Brompton where he assisted Dr Alex Lyon in setting up the specialist cardio-oncology service.
Co-Chair: Session 9 - Arrhythmia management in cancer patientsRead More...
Since starting in Poole in 2013, he has overseen the ongoing development of a comprehensive local cardiac MRI, CT and echo service with an extended outreach to neighbouring institutions as well as providing cardio-oncology input and imaging services for cancer patients in the Dorset Cancer Centre. His research interests include non-invasive imaging, in particular cardiac MRI with a focus on haematological (red cell) disorders leading to cardiac iron overload and its assessment. He has been an invited speaker at multiple local, national and international meetings. He is passionate about cardiology in general with a particular interest in imaging, both advanced echocardiography and cross-sectional imaging (cardiac CT and MRI). He is an examination board member for the European Association of Cardiovascular Imaging (EACVI) Section CMR and is a founding board member of the British Cardio-Oncology Society (BC-OS).
Vicki Chambers, BSc(Hons), RGN
Heart Failure Clinical Nurse Specialist, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom
Vicki qualified as a nurse in 1991 as a direct entry graduate from the University of Surrey with a BSc(Hons) in Nursing Studies. She worked for 2 years in acute medicine and then took up a post in a London cardiac tertiary centre where she gained her cardiac nursing qualifications. She has been a cardiac nurse specialist for 24yrs and worked in primary, secondary and tertiary care. She has worked as a project manager and a nurse manager.
Conference Topic: Session 10 - The Role of the Clinical Nurse Specialist in Cardio-OncologyRead More...
In 2004, she was awarded a NHS Health & Social Care Award for expanding a community cardiac rehabilitation service. During her career, she has undertaken further education in advanced communication, physical assessment, heart failure and end of life care. Vicki has been a Heart Failure Clinical Nurse Specialist since 2010 and now works in a London cardiac tertiary NHS hospital. Here she is involved in the care of patients with advanced and complex heart dysfunction. Her role involves working in the Cardio-Oncology Service. In April 2017, she had an abstract accepted for poster display at the European Society of Cardiology Heart Failure Congress. The abstract focused on the Clinical Nurse Specialist’s role in Cardio-Oncology. Member: British Society Heart Failure; European Society Cardiology; Royal College Nursing
Dr. Sarah Clarke, MA, MD, FRCP, FESC, FACC
Consultant Cardiologist, Papworth Hospital, Cambridge, United Kingdom. President, British Cardiovascular Society.
Dr Sarah Clarke MA MD FRCP FESC FACC, is a Consultant Cardiologist at Papworth Hospital, Cambridge and was elected President of the British Cardiovascular Society (BCS) in 2014, taking up office in June 2015 for a 3 year term. Dr Clarke trained in Cambridge and at the Massachusetts General Hospital in Boston, USA. She was appointed Consultant Cardiologist (Interventional Cardiology) at Papworth Hospital, Cambridge in 2002.
Co-Chair: Session 1Read More...
She was Clinical Director for Cardiac Services (2006-2012) and appointed Clinical Director for Strategic Development from 2012. She was cardiology lead for the design of New Papworth Hospital (opening 2018) on the Cambridge Biomedical Campus and is involved in the delivery of the transition programme. She has recently been appointed Clinical Lead for the Elective Care Working Group for the Cambridge and Peterborough CCG System Transformation Programme (includes cardiology, ophthalmology, orthopaedics and ENT). Dr Clarke is the Clinical Lead for the Cardiovascular Clinical Study Group at the Eastern Academic Health Science Network. She is the international editor of the e-newsletter of the ACC, a member of the Women in Cardiology Council at the ACC and Series Editor for Education in Heart. Formerly Vice President of Education and Research at the BCS (2011-2014), Dr Clarke reinvigorated the Annual Conference as the 'must go' meeting for general cardiology for trainees and trained cardiologists facing revalidation. She established new courses including the 'Year in Cardiology' held each year at the RCP and serialised in the European Heart Journal 5 years ago, and a course for industry employees to educate in general cardiology and the subspecialties.
Dr. Sinead Clarke, MB.CHB. Dip Pall Med. MRCGP.
GP Advisor, Macmillan Cancer Support; General Practitioner, Nantwich, United Kingdom
Sinead is a GP working in Nantwich Cheshire and has worked for Macmillan, first as a Macmillan GP and more recently as a GP Advisor for a number of years. She has had a career long interest in Cancer and leads on living with and beyond cancer for Macmillan and is also working as part of the team focussing on treatable but incurable cancers. When not working or acting as a taxi service for her son she enjoys swimming, hiking and reading science fiction novels.
Conference Topic: Session 5 - Raising Awareness of cardiotoxicity in primary care
Prof. Jane Dacre, MD, PRCP
President, Royal College of Physicians, London, UK
Professor Jane Dacre was elected president of the Royal College of Physicians in April 2014. She is an honorary consultant physician and rheumatologist at the Whittington hospital in North London, Professor of Medical Education and was Director of UCL Medical School in London before taking a secondment to become PRCP. Professor Dacre was also the medical director of MRCPUK until December 2013 and prior to that academic vice president of the RCP.
Conference Topic: Day 1 - Welcome MessageRead More...
Professor Dacre is a vice chair of the Academy of Medical Royal Colleges, was a GMC council member, and chaired the GMC education and training Committee (2008-2012) and leads a research programme in medical education focussing on assessment. Professor Dacre was the clinical lead for the development of the first Clinical Skills Centre in the UK, and was a co-author of the GALS screen. She has been instrumental in the development, implementation and evaluation of assessment systems in medicine. Professor Dacre won the medicine and healthcare category for the 2012 Women in the City Woman of Achievement Award; was named on the Health service journal’s inaugural list of 50 inspirational women in healthcare in 2013; was named in the science and medicine category for people of influence Debrett’s 500 in 2015, 2016 and 2017; and was named on the Health service journal’s top 100 list in both 2014 and 2015.
Prof. Sarah Darby, PhD
Professor of Medicine Statistics, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, England
Sarah C Darby is Professor of Medical Statistics in the University of Oxford. She studies Mathematics for her undergraduate degree, followed by a PhD in Medical Statistics at the London School of Hygiene and Tropical Medicine. After graduating, she worked at St. Thomas’ Hospital Medical School, the National Radiological Protection Board, and the Radiation Effects Research Foundation in Hiroshima before moving to the University of Oxford in 1984.
Conference Topic: Session 4 - Radiation-related heart disease: where are we now?Read More...
Professor Darby is a member of the secretariat of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), which carries out meta-analyses of individual patient data from randomised controlled trials of various treatments for breast cancer, and she leads the EBCTCG analyses of the effects of radiotherapy and surgery. In addition, she leads a number of studies to evaluate the long-term risk of heart disease and other serious side-effects from cancer treatments and she works on several studies to evaluate the risk of cancer from exposure to ionising radiation.
Dr. Susan Dent, MD, FRCPC
President, Canadian Cardiac Oncology Network; Professor, Department of Medicine, University of Ottawa; Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Dr. Dent is a Medical Oncologist at The Ottawa Hospital Cancer Centre and Professor in the Department of Medicine at the University of Ottawa. She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the National Cancer Institute of Canada Clinical Trials Group.
Co-Chair: Session 1Read More...
She is the research lead for the breast disease site group at the Ottawa Hospital Cancer Centre, and a member of the IND working group for the Breast Cancer Disease Site Committee of the National Cancer Institute for Canada Clinical Trials Group. Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity. She is the founder of the Ottawa Cardiac Oncology Program as well as the Canadian Cardiac Oncology Network, organizations dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity. She established the first multidisciplinary cardio-oncology clinic in Canada in 2008 and since that time has travelled around the world (India, China, Chile) assisting other centers in establishing similar clinics. She is active in cardio-oncology education, having co-authored 3 book chapters in cardio-oncology (2016/2017) and 3 position statements/guidelines (Canadian Cardiology Society, American Society of Clinical Oncology, European Society of Cardiology).
Prof. Helena Earl
Professor of Clinical Cancer Medicine; Honorary Consultant Medical Oncologist, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Professor Helena Earl completed a PhD in Breast Cancer in 1985 and specialist training in Medical Oncology with General Internal Medicine at UCLH in 1991. In 1992 she joined the University of Birmingham and was Director of the Cancer Research UK Clinical Trials Unit, moving to the University of Cambridge, Department of Oncology in 1996. She is active in clinical and translational research and leads NCRN clinical trials in breast cancer (NEAT, tAnGo, Neo-tAnGo, ARTemis, PERSEPHONE, and PARTNER).
Co-Chair: Day 1 - Plenary LectureRead More...
Professor Earl holds grant funding from Cancer Research UK, the NIHR HTA, and pharmaceutical partners. She is a PI in the Cancer Research UK Cambridge Cancer Centre, NIHR BRC, ECMC, CCTC, and Cambridge Breast Cancer Research Unit. She is an active member of the Cambridge Trials Methodology Group developing linked Bayesian Adaptive Randomised (BAR) designs, with biomarkers and new treatments, integrating early biomarkers of response into these designs. Professor Earl has published her research in cardio-oncology from the PERSEPHONE Trial of adjuvant trastuzumab duration.
Prof. Sara Faithfull, PhD, MSc, BSc(Hons), RN
Professor of Cancer Nursing Practice, Lead for Clinical Innovation, University of Surrey, Surrey, UK
Sara trained as a cancer nurse in 1986 at the Royal Marsden Hospital (UK) and has worked in many oncology-related fields including neuro-oncology, radiotherapy and urology. She undertook her BSc after qualifying as a nurse and has always been passionate about combining the role of the nurse with that of a researcher. Sara was the recipient of the Smith and Nephew Nursing fellowship in 1991 and a CR-UK Nursing Research Fellowship in 1994.
Conference Topic: Session 5 - Managing cardiovascular risk in cancer patients in primary careRead More...
She obtained her Ph.D. from the Institute of Cancer Research in 2000. She was President of the European Oncology Nursing Society and continues to work with the European Society for Radiation Oncology (ESTRO). She is co-editor of ESTRO’s Technology Innovations and Patient Support in radiation Oncology (tipsRO). Championing the support for people who continue to experience consequences of cancer and its treatment Sara has worked with clinical teams and patient groups to provide better after care especially for those men with prostate cancer. Continuing as a specialist clinical adviser as part of the Macmillan consequences of cancer treatment team she has helped develop patient resources, clinical training and professional standards. Sara has over 80 academic publications and contributed as an author to several oncology text books. Sara has a strong interest in men’s health and has worked in multiple service related projects to support men with prostate cancer, she is a trustee of PCUK charity. As a clinical academic at Surrey University she is a lead for Clinical Innovation.
Prof. Dimitrios Farmakis, MD, PhD, FESC
Assistant Professor, National and Kapodistrian University of Athens, European University of Cyprus, Piraeus, Greece
Professor Farmakis graduated from the Medical School of the National and Kapodistrian University of Athens in 1996 and received his Doctoral Degree on haemoglobinopathy-associated heart disease from the same university in 2003. He specialized in Cardiology at Athens University Hospital “Attikon” and received his board certification in 2008.
Conference Topic: Session 9 - Practical matters in atrial fibrillation - anticoagulation & rhythm managementRead More...
He was further trained in Cardio-Oncology at Bern University Hospital “Inselspital”, Bern, Switzerland, in Heart Failure at Zurich University Medical School, Zurich, Switzerland, and in Clinical Trials at Harvard Medical School, Boston, U.S.A., by which he was awarded a distinction. Dr. Farmakis is the current President of the Working Group for Cardiomyopathies and Basic Research of the Hellenic Society of Cardiology, a Fellow of the European Society of Cardiology (ESC), a member of the Heart Failure Association (HFA) of the ESC, a member of the Cardio-Oncology Committee of the HFA and a member of the Board of the Hellenic College of Cardiology. Dr. Farmakis has been working as a cardiologist with clinical, educational and research duties at the Medical School of the National and Kapodistrian University of Athens since 2008. Since 2012, he is in charge of the Cardiac Clinic for Haemoglobinopathies at Athens University Hospital ”Laiko” and oHoShsince 20since 2015, he runs the Cardio-Oncology Clinic at Athens University Hospital “Attikon”. In 2017, Dr. Farmakis was elected an Assistant Professor of Pathophysiology at the European University of Cyprus. His research activity has been focused on heart failure, haemoglobinopathies, cardiovascular pharmacology and cardio-oncology. In total, Dr. Farmakis has published more than 200 papers, 175 of which in international journals indexed in PubMed with a total impact factor of 1020.531, a total number of citations of 5161 and a h index of 43. He has further contributed to 66 chapters in international and Greek educational textbooks. He has been invited as a speaker in 110 international and national congresses and participated with abstracts in 208 international and national congresses. He has received research grants and awards for research protocols and served as a primary investigator or steering committee member in research projects funded by the European Commission. He also sits on editorial boards of international medical journals and on other scientific, advisory or guideline committees.
Dr. Michael Fradley, MD
Assistant Professor of Medicine, University of South Florida; Director, Cardio-Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Dr. Fradley is an Assistant Professor of Medicine at the University of South Florida with a joint appointment as an Assistant Member at the H. Lee Moffitt Cancer Center and Research Institute. He is the director of the combined Moffitt Cancer Center-University of South Florida Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine.
Judge: Session 6 - Young Investigator CompetitionRead More...
He remained at Johns Hopkins for internal medicine residency and then went on to complete fellowships in both cardiology and clinical cardiac electrophysiology at Massachusetts General Hospital. His research focuses on all aspects of cardio-oncology, however as a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He has co-authored numerous articles in the field of cardio-oncology. He is also actively involved in undergraduate and graduate medical education mentoring medical students, residents and fellows. He developed and serves as the program director for cardio-oncology fellowship at the University of South Florida and Moffitt Cancer Center. He is the co-director of the biomedical research tract in the Scholarly Concentrations Program at the University of South Florida, Morsani College of Medicine. He is also the medical director for the Harvey Simulation Elective and teaches the cardiovascular pathophysiology course for the second year medical students.
Dr. John Groarke, MBBCh, MSc, MPH, MRCPI
Associate Physician, Division of Cardiovascular Medicine, Brigham and Women's Hospital; Cardio-Oncologist, Dana Farber Cancer Institute, Instructor of Medicine, Harvard Medical School, Boston, MA, USA
Having graduated with honors and academic awards from medical school at Trinity College Dublin, Ireland, Dr. Groarke completed internal medicine residency and general cardiology fellowship, receiving a Certificate of Completion of Specialist Training from the Royal College of Physicians of Ireland. He then completed clinical fellowships in advanced cardiovascular imaging, cardio-oncology, and advanced heart failure/mechanical circulatory support/heart transplantation at Brigham & Women’s Hospital, Boston between 2011 and 2015.
Conference Topic: Session 4 - Radiation-induced autonomic dysfunctionRead More...
In July 2015, he was appointed as an associate physician with the Division of Cardiovascular Medicine, BWH and Cardio-Oncology Program at Dana Farber Cancer Institute, and as an Instructor of Medicine at Harvard Medical School. In this role, he offers subspecialty expertise in advanced heart failure, mechanical circulatory support, heart transplantation, cardio-oncology, and cardiopulmonary exercise testing. Dr. Groarke has completed a Masters in Science through Trinity College Dublin, and a Masters in Public Health through Harvard School of Public Health. He represents Harvard University on a national expert clinical research committee called the Heart Failure Apprentice Network (HFAN) – a clinical research initiative funded by the National Heart Lung and Blood Institute. His primary clinical research focus is in the field of cardio-oncology, a dynamic and evolving cardiology subspecialty committed to improving the cardiovascular wellbeing of the growing population of cancer survivors. He has secured institutional and industry funding to develop cardio-oncology clinical research across BWH and DFCI. He has made meaningful contributions to cardio-oncology clinical research literature, and is regularly invited to speak at national and international conferences.
Dr. Mark Harbinson, MB, BCh, BAO (Hons), MMedSc, MD, FRCP
Senior Lecturer, Centre for Medical Education, School of Medicine, Dentistry and Biomedical Science, Queen’s University Belfast; Consultant Cardiologist, Belfast Trust, Belfast, Northern Ireland, United Kingdom
Dr Mark Harbinson is Senior Lecturer in the Centre for Medical Education, School of Medicine, Dentistry and Biomedical Science, Queen’s University Belfast and Consultant Cardiologist, Belfast Trust. He graduated from Queen’s University Belfast and trained in cardiology in Northern Ireland and at Imperial College/Royal Brompton Hospital in London.
Co-Chair: Session 4 - Radiation therapy and long-term cardiovascular complicationsRead More...
His clinical interests include heart failure and cardiac imaging (nuclear cardiology, CMR and echocardiography), and he has supervised several MD and PhD students in these areas. He is past president of the British Nuclear Cardiology Society. He runs a cardio-oncology service within Belfast Trust, which is the regional centre for cancer management in Northern Ireland. He is a member of the Committee of the British Cardio-Oncology Society.
Prof. Sian Harding
Professor of Cardiac Pharmacology, National Heart and Lung Institute, Imperial College; Head, Division of Cardiovascular Sciences and Director of the Imperial British Heart Foundation Cardiovascular Regenerative Medicine Centre, London, United Kingdom
Professor Sian Harding is Professor of Cardiac Pharmacology at NHLI, Imperial College London; Head of the Division of Cardiovascular Sciences and Director of the Imperial British Heart Foundation Cardiovascular Regenerative Medicine Centre. Her work has centered on the myocardium in heart failure, especially beta-adrenergic mechanisms.
Conference Topic: Session 8 - iPSC models to study cardiotoxicityRead More...
She was PI on the first UK Gene therapy Trial in LVAD patients, aimed at improving cardiac contractility. She is now studying the pluripotent stem cell-derived cardiomyocyte, both for disease modelling and cardiac repair. Professor Harding is former President of the European Section of the International Society for Heart Research and member of the Nuffield Council on Bioethics. She has been elected Fellow of both the American Heart Association and the European Society of Cardiology, and is on the Board of the British Society of Gene and Cell Therapy.
Dr. Eric Harrison, MD
Medical Director, Tampa Memorial Hospital;, Cardiologist, Harrison Cardiovascular Centre, Tampa, FL, USA
Dr. Harrison is currently the National Director of Advanced Cardiac Imaging of Iasi Healthcare Inc . which owns and operates 15 acute care hospitals in Florida, Texas, Louisiana, Utah, Arizona, and Nevada. Dr. Harrison was one of first to use the therapeutic hypothermia for Cardiac Arrest patients. He began to use this treatment clinically shortly after the landmark articles were published in February 2002.
Co-Chair: Session 7 - Cardio-Oncology and Haemato-OncologyRead More...
He is currently integrating hypothermic medicine into the IASIS healthcare system. He has served as a consultant for many national companies associated with cardiac imaging. Dr. Harrison started and directs the Joint Memorial Hospital / University of South Florida Medical School Advanced Cardiac Imaging Program for practicing physicians , cardiac fellows, and medical student training. He is a preceptor for the University of South Florida Medical School and Saba University Medical School of the Netherland Antilles. Dr. Harrison received his medical degree from the University of Kentucky and completed internship, Internal Medicine residency and Cardiology Fellowship at the University of South Florida where he was a Special Fellow of the Florida Heart Association. He was acting Director of the Cath Lab at the VA Hospital for 3 month prior to finishing his training. He is a founding physician of the University of South Florida Medical School. Dr. Harrison's experience in cardiology covers a broad spectrum. He was co-director of the Cardiology Center at Tampa General Hospital for thirteen years and directed noninvasive cardiology for seven years where he started echocardiography and nuclear cardiology. At Tampa General he performed over 14,000 heart catheterizations, numerous coronary angioplasties, cardiac electrophysiologic studies and myocardial biopsies and was a transplant cardiologist on the transplant team for three years. His first transplant patient has survived over 20 years. He and his colleagues started the first outpatient cardiovascular health center in Tampa at Memorial Hospital where he is currently the Medical Director and where he has directed the cardiac rehabilitation program. His non-invasive cardiology interests are 3D echo, multislice CAT scan imaging of the coronaries, Cardiac PET/CT, Cardiac MRI, and hybrid imaging.
Dr. Joerg Herrmann, MD
Associate Professor of Medicine; Director, Cardio-Oncology Clinic; Research Director, Ischemic Heart Disease Program , Mayo Clinic College of Medicine, Rochester, MN, USA
Dr. Joerg Herrmann completed his medical school curriculum at the Ruhr University in Bochum, Germany with a doctoral thesis on EGF receptor expression in gynecological malignancies. Thereafter, he worked in the Department of Internal Medicine and Cardiology at the University Clinic Essen until his post-doctoral research fellowship at the Mayo Clinic Rochester in 2000. Studies on the ubiquitin-proteasome system in atherosclerosis and use of proteasome inhibitors eventually led to the interest in the cardiovascular side effects of cancer therapeutics.
Conference Topic: Session 10 - Toolkit for success - real world optionsRead More...
At the Mayo Clinic in Rochester, following completion of residency in internal medicine and fellowship in cardiovascular diseases and interventional cardiology, he joined the Department of Cardiovascular Diseases in 2011. He currently is an Associate Professor of Medicine at the Mayo Clinic College of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program. His research interests focus on all aspects of cardio-oncology and the pathophysiology, diagnosis, and treatment of atherosclerosis. He holds an NIH-K08 grant on the pathophysiological role of the immunoproteasome in atherosclerosis. He has published over 100 articles in peer-reviewed journals including the New England Journal of Medicine and Nature Reviews. He serves as a reviewer for over 30 peer-review journals, as well as the NIH, the Dutch Heart Foundation, the Dutch Cancer society, and the British cancer society. He is also a contributor to Braunwald’s Heart Disease, the associated editor of Trends in Cardiovascular Medicine and PracticeUpdate Cardiology, and is the editor of the just recently published textbook Clinical Cardio-Oncology.
Prof. Denise Hilfiker-Kleiner
Professor of Molecular Cardiology & Dean of Research, Hannover Medical School, Hannover, Lower Saxony, Germany
Denise Hilfiker-Kleiner received her PhD in 1994 at the University of Zurich and Emory University, Atlanta and her Habilitation 2006 at Hannover Medical School (MHH). She is dean of research of the MHH and leads the Department of Molecular Cardiology. She has a longstanding experience in analyzing signaling pathways in cardiac cells relevant for cardiac physiological and pathophysiological processes. In this regard she explores endogenous regeneration abilities of the heart after pregnancy induced stress, cancer disease and/or treatment with cardio toxic agents.
Conference Topic: Session 8 - New strategies to protect the heart from cancer therapiesRead More...
She is a member of a commission which counsels the German Council of Science and Humanities of the German Federal Government and the State. She is a member of the ESC Program Committee, a founding member of the study group on PPCM and of the translational research group of the Heart Failure Association (HFA) of the ESC. She is a core PI of the REBIRTH Excellence Cluster at the MHH and the lead scientist and organizer of the multicenter clinical trial on the efficacy of Bromocriptine in PPCM funded by the German Federal Ministry of Education and Research (BMBF).
Dr. David Hodgson, MD, MPH
Professor and Clinician Scientist, Department of Radiation Oncology, Institute of Health Policy, Management and Evaluation, University of Toronto; Staff Oncologist, Princess Margaret Cancer Centre, Toronto, ON, Canada
Dr. Hodgson is a Professor and clinician scientist in the Department of Radiation Oncology, and the Institute of Health Policy, Management and Evaluation, University of Toronto, and a staff oncologist at the Princess Margaret Cancer Centre in Toronto. He is the Medical Director of the Pediatric Oncology Group of Ontario (POGO) and the POGO Chair in Childhood Cancer Control at University of Toronto.
Conference Topic: Session 4 - A Practical Guide to Minimizing Radiation-related CardiotoxicityRead More...
His research activities include the development of lymphoma clinical trials for COG, and studies linking normal tissue dosimetry to late effects among young cancer survivors and the evaluation of strategies to optimize long-term health outcomes.
Dr. Christopher B. Johnson, MD, FRCP
Assistant Professor of Medicine, University of Ottawa; Cardiologist, The Ottawa Hospital, Ottawa, ON, Canada
Dr. Johnson obtained his MD (Magna Cum Laude) from the University of Ottawa in 1998, then completed internal medicine residency and cardiology fellowship at the University of Ottawa. He obtained additional fellowship training in echocardiography and nuclear cardiology at the University of Ottawa Heart Institute. Dr. Johnson is an Assistant Professor of Medicine in the Division of Cardiology at the University of Ottawa.
Co-Chair: Day 1 Plenary SessionRead More...
Dr. Johnson is site director for cardiology at the General Campus of the Ottawa Hospital where his practice focuses on cardiac imaging and clinical cardiology in special populations, including cardio-oncology where his educational innovations have received national recognition. Dr. Johnson participates in clinical research related to cardio-oncology and medical education research including the role of eConsults in CME. As a clinician educator at the University of Ottawa, Dr. Johnson is active in teaching medical students, residents, and cardiology fellows, and is the Department of Medicine Postgraduate Medical Education Director. He is a regular speaker and organizer of national education events related to cardiovascular disease and cardiac imaging.
Dr. Anna Kirby, BA (Hons) MBBChir MA (Cantab) MRCP FRCR MD(Res)
Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust, London, UK
Dr Anna Kirby is a Consultant Clinical Oncologist specialising in the treatment of patients with breast cancer. She leads research into novel breast radiotherapy techniques at the Royal Marsden and Institute of Cancer Research. She is Chief Investigator of the UK HeartSpare study, and breast lead investigator on the CORE trial evaluating the role of stereotactic radiotherapy in treating metastatic disease.
Co-Chair: Session 4: Radiation therapy and long-term cardiovascular complicationsRead More...
Dr Kirby graduated from Cambridge University in 1995 with a first-class honours degree in Medicine and Psychology. Her specialist oncology training was completed at The Royal Marsden and Guy’s and St Thomas’ Hospitals following which she undertook a research degree at the Institute of Cancer Research. Her publications describe methods for improving the accuracy of breast cancer radiotherapy and for reducing late side-effects of treatment including heart disease. Her work in heart-sparing breast radiotherapy has changed national practice. Her current research interests include combining breath-hold and volumetric-modulated arc therapy to minimise heart and lung doses in women with lymph-node positive breast cancer, reversing the order of breast cancer treatments to reduce the impact of radiotherapy on breast reconstructions, and investigating the applications of MR-linac technology to the treatment of breast cancer. Dr Kirby is an Examiner for the Royal College of Radiologists (RCR) and a member of the RCR Professional Support and Standards Board. She is also a keen singer.
Prof. Michael Kirby, FRCP
Visiting Professor to the Faculty of Health & Human Sciences, University of Hertfordshire, Hatfield, Hertfordshire; The Prostate Centre, London, United Kingdom
Professor Michael Kirby worked as a GP in Letchworth, Hertfordshire from 1973 until 2007, and was Director of HertNet (the Hertfordshire Primary Care Research Network) from 1998 until 2007, and Consultant to the Clinical Trials Unit. He held two cardiology sessions at the local DGH throughout his GP career. He is now Visiting Professor to the Faculty of Health and Human Sciences, at the University of Hertfordshire, and previously, Visiting Professor to the Institute of Diabetes for Older People, (IDOP) at the University of Bedfordshire.
Conference Topic: Session 5 - Managing cardiovascular risk in cancer patients in primary careRead More...
His clinical work is now at The Prostate Centre in London, where he deals with complex medical problems. Professor Kirby is an Associate Member of the British Association of Urological Surgeons and a Fellow of the Royal College of Physicians. He has been an active member of the Department of Health Prostate Cancer Risk Management Working Party and the Prostate Cancer Advisory Group, also, advisor to the Sexual Dysfunction Association. His special interests include cardiology, diabetes, osteoporosis, men’s health, urology and education. He is Editor in Chief of the Primary Care Cardiovascular Journal, on the editorial board of the British Journal of Primary Care Nursing, the British Journal of Cardiology, Geriatric Medicine and the International Journal of Clinical Practice. He has also held membership of several NHS advisory boards. He has published more than 400 clinical papers and 30 books.
Dr. Bonnie Ky, MD, MSCE
Assistant Professor of Medicine and Epidemiology, Division of Cardiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Dr. Bonnie Ky, MD, MSCE is an Assistant Professor of Medicine and Epidemiology at the University of Pennsylvania School of Medicine Division of Cardiology, a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics, is the Director of the Penn Center for Quantitative Echocardiography, and Penn Cardio-oncology Research Program.
Co-Chair: Day 1 Plenary LectureRead More...
In this role, she leads a highly active NIH-funded translational research program aimed at identifying the underlying mechanisms and predictors of cancer therapy cardiotoxicity in many populations, including breast, renal cell, lung cancer and lymphoma. Specifically, her study objectives are to determine the role of mechanistic biomarkers and echocardiography-derived measures of myocardial mechanics in understanding and predicting incident cardiotoxicity and adverse cardiovascular outcomes with cancer treatment. She has specialized training in clinical epidemiology, the study of cardiovascular biomarkers, and the use of quantitative echocardiography as tools to understand cardiac remodeling and risk prediction. Dr. Ky received her a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology. She received her Doctor of Medicine degree from the University of Pennsylvania School of Medicine. She completed her residency and cardiology fellowship as well as a Masters of Science in Epidemiology at the University of Pennsylvania. She is a member of the American College of Cardiology (Cardio-oncology Executive Council, Program Committee Leader, Cardio-Oncology Course Director), American Heart Association (Expert Consensus Writing Committees), American Society of Echocardiography (Cardio-oncology Guidelines Writing Committee), American Society of Clinical Oncology (Cardiac Dysfunction in Survivors Writing Committee), Heart Failure Society of America (Chair, Research Committee), International Cardio-Oncology Society (Director, Scientific Committee), and National Cancer Institute (NCI) Community Oncology Cardiotoxicity Task Force.
Dr. James Larkin, MA, FRCP, PhD
Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, London, UK
Dr James Larkin is a Consultant Medical Oncologist specialising in the treatment of melanoma and cancers of the kidney. Dr Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at the ICR which led to the award of a PhD.
Conference Topic: Session 2 - The impact of immunotherapy in treating solid tumoursRead More...
He completed specialist training at The Royal Marsden and was appointed a Consultant in 2008. His research interests involve trying to understand cancer and its consequences better as well as developing improved treatments, particularly with targeted therapies and immunotherapies. He is a medical advisor to the patient advocacy group Melanoma UK, a trustee of the Kidney Cancer Support Network and the only non-US member of the Board of Directors of the Kidney Cancer Association. He is a past NIHR National Specialty Lead for Early Phase Oncology Trials as well past Chair of both the NCRI Renal Cancer Clinical Studies Group and The Royal Marsden/ICR Committee for Clinical Research. He is currently Vice Chair of the Cancer Research UK Clinical Research Committee and Lead of the Uncommon Cancers Theme at the Royal Marsden/ICR Biomedical Research Centre for Cancer.
Dr. Daniel Lenihan, MD
President, International Cardio-Oncology Society; Professor of Medicine; Director, Cardio-Oncology Center of Excellence, Washington University at St Louis, St Louis, Missouri, USA
Dr. Lenihan, has been active in cardio-oncology and heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.
Conference Topic: Session 1 - Opening Address
Chair: Session 6 - Young Investigator Competition
Co-Chair: Plenary Lecture - Long-Term Cardiovascular Outcomes in Survivors of Hodgkin's LymphomaRead More...
His current projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the PI of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for multiple myeloma and recently completed the PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity and has been intimately involved in the latest treatment trials for cardiac amyloidosis. He recently moved to Washington University in St Louis to enhance and expand their Cardio-Oncology Center of Excellence. Dr Lenihan continues to enhance and foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current president of the International Cardio-Oncology Society (ICOS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Dr. Gill Levitt
Honorary Consultant Paediatric Oncologist, Great Ormond Street Hospital for Sick Children NHS Foundation Trust, London, United Kingdom
Dr. Gill Levitt is an honorary Consultant Paediatric Oncologist at the Great Ormond Street Hospital for Children, London. Her work has involved the care of children diagnosed with solid tumours, with research interests in renal tumours, Hodgkns disease and the late consequences of cancer treatment with particular interest in treatment induced cardiac disease.
Conference Topic: Session 5 - Lessons from paediatric oncology: How to organize long-term cardiovascular surveillance in cancer survivorsRead More...
Her previous appointments include chairperson for the National Cancer Research Institute Children’s Cancer and Leukaemia Renal tumour subgroup, member of the International Society of paediatric oncology (SIOP) renal tumour committee and member and past chairperson of the Children’s Cancer and Leukaemia group (CCLG) Late effects group. Dr. Levitt was very involved with the Department of Health National cancer survivorship initiative 2008-13 as the National Clinical lead for the children’s and young people workstream and national advisor to the adult work stream. Since her retirement the NCSI work has continued via her role as clinical advisor for Macmillan. She held a EEC FP7 grant 2011-17 with the remit of standardising Long term follow-up guidelines for the care of survivors of childhood and adolescent cancer within Europe and worldwide via the International Late Effects of Childhood Cancer Guideline Harmonization Group. In addition she has contributed to the work on transition of adolescence to adult services across all diseases and is a founder member of the British Cardio-oncology Society.
Dr. Teresa Lopez-Fernandez, MD
Noninvasive Cardiologist, Cardiac Imaging Unit and Cardio-oncology Unit, La Paz University Hospital, Madrid, Spain
Teresa López-Fernández, MD, is a noninvasive cardiologist in the Cardiac Imaging Unit and Cardio-Oncology Unit, at La Paz University Hospital, Madrid, Spain. Her clinical and research focus include the mechanisms, diagnosis and treatment of cardiac complications of cancer therapies. Her clinical cardiac imaging expertise includes advanced training in echocardiography, 3D echocardiography, and stress echocardiography.
Co-Chair: Session 6 - Young Investigator CompetitionRead More...
Dr. López-Fernández is a member of the Spanish Society of Cardiology Cardiac Imaging Board and Cardio oncology working group board. She is also a Task Force Member for the development of a position paper on anticancer treatments and cardiovascular toxicity developed under the auspices of the Committee for Practice Guidelines of the European Society of Cardiology. Dr. López-Fernández obtained her degree in Medicine and Surgery in from the Universidad Complutense de Madrid (Spain) in 1996, followed by an I.R. Residence in Cardiology in the Hospital Fundación Jiménez Díaz, in Madrid (1997-2002). In 2004, she obtained her accreditation in advanced Echocardiography by the Spanish Society of Cardiology. Dr. López-Fernández completed additional certifications in Adult Transthoracic Echocardiography (2013) and Adult Transesophageal Echocardiography (2014) by the European Society of Cardiology.
Dr. Alexander Lyon, MA, BM, BCh, PhD, FRCP, FHFA
GCOS 2017 Co-Chair; Senior Lecturer in Cardiology, Imperial College London; Consultant Cardiologist & Clinical Lead for Cardio-Oncology Service, Royal Brompton Hospital, London, United Kingdom. President of the British Cardio-Oncology Society.
Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome, and the development of novel therapeutics including gene therapy for chronic heart failure.
GCOS 2017 Co-ChairRead More...
Alex is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. Alex is the current president of the British Cardio-Oncology Society (formerly the UK Cardio-Oncology Consortium) and he is the cardiology advisor to the charity Macmillan Cancer. Alex was recently appointed chair of the European Society of Cardiology Heart Failure Association Cardio-Oncology Study Group and he is a co-author of their ESC Position Statement on Cardio-Oncology. He is a member of the International Cardio-Oncology Society and is co-chair of the 2017 ICOS-BCOS hosted Global Cardio-Oncology Summit in London.
Prof. Jane Maher
Consultant Clinical Oncologist, Mount Vernon Cancer Centre and Hillingdon Hospital; Chief Medical Officer, Macmillan Cancer Support, London, UK
Jane became Macmillan’s Chief Medical Officer in 1999. She is an NHS clinical leader, and a Consultant Clinical Oncologist at Mount Vernon Cancer Centre and Hillingdon Hospital, where she has worked for more than 20 years. Jane is also a senior clinical lecturer at University College London and Visiting Professor in Cancer and Supportive Care at the Centre for Complexity Management at Hertfordshire University.
Session 1 Keynote Lecture: Cancer survivorship and the impact of cardiovascular diseaseRead More...
In her role at Macmillan, Jane provides medical services advice at board and senior management level and supports the charity's links with the royal colleges, universities, the Department of Health and the NHS. She has had a long term interest in consequences of cancer treatments. Her activity in this area includes chairing the Maher Committee for the Department of Health in 1995, leading the UK National Audit of Late Effects Pelvic Radiotherapy for the RCR in 2000 and most recently chairing the National Cancer Survivorship Initiative Consequences of Cancer treatments committee. She has written more than 100 published articles and is a National Clinical Advisor for Aftercare and Survivorship for NHS Improvement and UK representative for cancer survivorship in Europe.
Dr. Charlotte Manisty, MBBS, MA, MRCP, PhD
Senior Lecturer, University College London; Consultant Cardiologist, Barts Heart Centre and University College Hospitals, London, United Kingdom
Charlotte Manisty is a Senior Lecturer at University College London and a Consultant Cardiologist at the Barts Heart Centre and University College Hospitals, London. She specialises in heart failure and cardiac imaging, and has set up and leads the cardio-oncology service at Barts. Her medical training was undertaken at Oxford University and Imperial College, and she was awarded a Wellcome Trust Fellowship for her PhD in cardiorespiratory physiology in heart failure.
Conference Topic: Session 7 - How to manage cardiac problems in the bone marrow transplant patientRead More...
Current research interests include optimising imaging acquisition and analysis methods for identifying patients at risk of developing heart failure, using MRI-based scar imaging to improve ablation in patients with ventricular arrhythmias, and understanding and treating patients with cardiac problems arising from cancer therapies with a particular interest in multiple myeloma. She has also completed a study commissioned by the Medicines and Health Regulatory Authority to assess the risk of cardiotoxicity related to metal-on-metal hip implants. She receives funding for her work from British Heart Foundation, Barts Charity and the National Institute for Health Research, and supervises several PhD students. She is author of over 60 publications and book chapters, and is regularly invited to speak both Nationally and at International conferences.
Prof. Theresa McDonagh, MD, FRCP, FESC
Consultant Cardiologist, and Clinical Lead for Cardiology and Heart Failure, King's College Hospital, London, UK
Professor McDonagh qualified from the University of Edinburgh and completed her internal medicine training there. She trained in Cardiology at the Western Infirmary in Glasgow. Her main research was on the epidemiology of Left Ventricular Dysfunction and Natriuretic Peptides hormones.
Co-Chair: Session 10 - How to deliver a successful cardio-oncology serviceRead More...
Subsequently she was appointed as a Senior Lecturer at the University of Glasgow and Glasgow Royal Infirmary where she ran the Heart Failure Service and was the Cardiologist involved in the Heart Transplant Programme (1999-2004). Following this she was a Consultant Cardiologist at the Royal Brompton Hospital, London (2004-2011) where led the Heart Failure Service, before moving to King's College Hospital to head up the Heart Failure Programme. Her main research interests are in novel biomarkers for heart failure and the delivery of heart failure services. She is a past Chair of the British Society for Heart Failure a Past Chair of the Clinical Section of the Heart Failure Association of the European Society of Cardiology. She is the Clinical Lead for the National Heart Failure Audit.
Dr. John McGowan, MBChB, MRCP
Clinical Research Associate, The Hatter Cardiovascular Institute, University College London; Honorary Cardiology Research Fellow, University College Hospital, London, United Kingdom
Dr John McGowan is a Cardiology Specialist Trainee in the north west of England. He studied medicine at the University of Manchester and attained a Cardiology National Training Number in 2012. His interests are in heart failure and the effects of cancer treatment on the cardiovascular system. He is currently undertaking research at The Hatter Cardiovascular Institute, University College London, to be submitted for an MD(Res).
Conference Topic: Session 10 - Physician Training in Cardio-OncologyRead More...
He is investigating potential cardioprotective strategies against anthracycline-induced cardiotoxicity. John is the Trainee Representative of the British Cardio-Oncology Society.
Dr. Dragana Milojkovic
Consultant Haematologist, Hammersmith Hospital; Honorary Senior Lecturer, Imperial College London, London, UK
Dragana Milojkovic is a consultant haematologist at Hammersmith Hospital with a focus on myeloid malignancies, in particular chronic myeloid leukaemia, myeloproliferative disorders and transplantation. Dr Milojkovic is also an honorary senior lecturer in haematology for Imperial College, London with post graduate teaching and research commitments.
Conference Topic: Session 7 - BCR-Abl inhibitors and cardiovascular toxicityRead More...
Dr Milojkovic is the director of the clinical trials unit at Hammersmith Hospital and is actively involved in the clinical trials for chronic myeloid leukaemia (CML) and myeloproliferative disorders (MPD) which are currently in place which include tyrosine kinase inhibitor therapy for newly diagnosed and resistant patients, strategies to tackle MRD in CML and novel agents in MPD. She is a member of national and European working parties including those in CML, MPD and also the European Society for Blood and Marrow Transplantation Chronic Malignancy. Prior to her appointment at Hammersmith, Dr Milojkovic was at King’s College Hospital, London where she specialised in myeloid malignancies including the myelodysplastic syndromes. Dr Milojkovic undertook her PhD at The Leukaemia Sciences Laboratory, The Rayne Institute, GKT School of Medicine in Immunobiology; studying the leukaemic microenvironment and immune suppression in myeloid malignancies. She has published extensively in peer reviewed journals regarding the biology and clinical management of CML, MPD and haematopoietic stem cell transplantation.
Dr. Javid Moslehi, MD
Director, Vanderbilt Cardio-Oncology, Vanderbilt University Medical Centre, Nashville, TN, USA
Dr. Moslehi is an Assistant Professor of Medicine and the Director of the Cardio-Oncology Program at Vanderbilt School of Medicine. He graduated from Johns Hopkins University and University of Connecticut School of Medicine. He then completed an internal medicine residency at Johns Hopkins Hospital.
Conference Topic: Session 2 - Cardiotoxicity caused by immunotherapyRead More...
Following the completion of clinical cardiology fellowship at the Brigham and Women's Hospital and Harvard Medical School, he started a basic science post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis (formation of new blood vessels) in heart disease. In 2009, he founded the Cardio-Oncology program at Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School with a clinic and research program focused on the cardiovascular care for cancer patients and cancer survivors. In 2014, he joined Vanderbilt. Dr. Moslehi is an expert clinician on the management of cardiac complications associated with radiation and both novel and traditional chemotherapies. His clinic and research program is focused on the mechanisms of toxicities associated with novel targeted therapies and how this knowledge can be modulated to understand human cardiovascular biology.
Dr. Kate Newbold, MD, MB ChB, MRCP, FRCR
Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust, London, UK
Dr Kate Newbold is a Consultant in Clinical Oncology at The Royal Marsden NHS Foundation Trust, London and Sutton, UK and a Senior Lecturer at The Institute of Cancer Research. She heads the Thyroid Unit at the Royal Marsden and chairs the NCRI thyroid cancer clinical studies group. Dr Newbold trained in Clinical Oncology at The Royal Marsden and Guys & St Thomas’ Hospitals, London.
Co-Chair: Session 9 - Arrhythmia management in cancer patientsRead More...
Ongoing research interests include advanced imaging techniques to stratify and guide radiotherapy in Head & Neck cancer and novel systemic agents and biomarkers for thyroid cancer.
Dr. Ann Partridge, MD, MPH
Professor of Medicine, Harvard Medical School; Director, Adult Survivorship Program, Dana Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, USA
Ann Partridge, MD, MPH is a Professor of Medicine at Harvard Medical School, and the Director of the Adult Survivorship Program at Dana Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital, where she also leads the Program for Young Women with Breast Cancer at DFCI. As a medical oncologist and clinical and health services researcher, she has sought to improve the care and outcomes of patients with cancer by conducting research, and by developing innovative clinical programming.
Conference Topic: Session 3 - Cardiovascular risk with chronic oestrogen suppression: is there a risk?Read More...
Her diverse though inter-related research projects have focused on communications with cancer survivors, risk perceptions, decision-making and quality of life, behavioral aspects of cancer care including adherence with anti-cancer therapy, age and race disparities in breast cancer outcomes, understanding and intervening to improve survivorship care, long-term effects of cancer and cancer treatment, and the unique disease and issues facing young women with breast cancer. She has conducted a number of studies leading and/or collaborating with multidisciplinary teams and successfully enrolling scores of patients on multicenter cohorts and clinical trials. She has also mentored a number of trainees and junior faculty members toward successful clinical research careers. Her main research in recent years focuses younger women with breast cancer in light of the fact that they are more likely to suffer both physically and psychosocially after a diagnosis of breast cancer. In 2005, she co-founded the Program for Young Women with Breast Cancer. she serves as the director of this novel program that has both clinical and research components. The program was recently audited by the Centers for Disease Control and Prevention (CDC), and was noted to be unique, valuable to patients and a highly sustainable model of providing additional support and education to a young women with breast cancer (http://www.cdc.gov/cancer/breast/what_cdc_is_doing/grant.htm). In light of the success of this program, Dr. Partridge and her team were awarded a CDC contract to expand and enhance the program to improve health outcomes in young women with breast cancer throughout New England and beyond. In complement to their successful clinical program, Dr. Partridge has conducted a number of research studies enrolling patients from within and outside of the institutional program, and has established and serves as PI for the Young Women’s Breast Cancer Study (YWS), a multi-institutional cohort of young women with breast cancer. The study enrolled over 1300 women age 40 and young at diagnosis and she and her team have received peer-reviewed funding and published a number of papers based on this work. She has also been awarded an Improving Cancer Care Grant from the American Society of Clinical Oncology (ASCO) to develop and evaluate a web and print-based educational and supportive care intervention for young women with breast cancer, and recently completed a RCT to test our intervention (#NCT01647607). She has conducted clinical epidemiologic research focused on age and race disparities in breast cancer outcomes, and in 2016 was selected to serve as co-Chair of the ALLIANCE Breast Committee.
Dr. Juan Carlos Plana, MD
Chief, Clinical Operations of Cardiology, Department of Medicine, Baylor College of Medicine; Director, Cardio-Oncology Centre; Co-Director, Center for Advanced Cardiac Imaging, Baylor St. Luke’s Medical Centre, Houston, TX, USA
Dr. Juan Carlos Plana Gomez is Chief of Clinical Operations of the Section of Cardiology, Department of Medicine at Baylor College of Medicine, Director of the Cardio-Oncology Center, and co-Director of the Center for Advanced Cardiac Imaging at Baylor St. Luke’s Medical Center. He is the Don W. Chapman Chair in Cardiology and tenured Associate Professor of Medicine. Dr. Plana is board certified in Cardiology and Echocardiography.
Co-Chair: Session 2 - Immunotherapy ad Emerging CardiotoxicityRead More...
Dr. Plana earned his medical degree from Pontificia Universidad Javeriana, Santafé de Bogotá (Colombia). His extensive training included internship, residency, chief resident year and fellowship in Cardiovascular disease and Cardiac Imaging (echocardiography and Nuclear Cardiology) at Baylor College of Medicine. Dr. Plana’s academic career started at the University of Texas MD Anderson Cancer Center where he served as Director of Cardiac Imaging and Medical Director of the Echocardiography laboratory. In 2010, he was recruited to Cleveland Clinic, where he opened as served as Co-Director of the Cardio-Oncology center. Dr. Plana's clinical and research interests include Cardio-Oncology, valvular heart disease, diseases of the aorta, and advanced cardiac imaging. The major focus of Dr. Plana’s clinical and scholarly interest is the development and application of novel echocardiographic techniques in the early detection of cardiac dysfunction caused by chemotherapeutic agents. His work has led to 38 reports published in the peer-reviewed literature, as well as 8 invited reviews and book chapters. He authored the Expert consensus for multi-modality Imaging evaluation of cardiovascular complications of radiotherapy in adults, and more recently chaired the Expert consensus for the multi-modality Imaging evaluation of adult patients during and after cancer therapy: a joint effort of the American Society of Echocardiography and the European Association of Cardiovascular Imaging. His national and international stature in the field of Cardio-Oncology and cardiac imaging is reflected by his 122 invited presentations at national and international conferences; his invited service to 5 journal editorial boards (including his current service to the International Board of the Journal of Cardiovascular Echocardiography); and his invited service to, and leadership of multiple committees of the American Society of Echocardiography (for which he currently serves on the Board of Directors) and other professional societies (representing the United States on the Echocardiography Section of the Inter-American Society of Cardiology) , as well as to the NIH (NCI/NHLBI) (member of the Expert Panel on Cardio-toxicity) and the FDA. In addition to his scholarly efforts, Dr. Plana has been a dedicated educator, having received major teaching awards from BCM (Excellence in Teaching Award, 2000), M.D. Anderson Cancer Center (Teacher of the Year Award, Section of Cardiology, U. Texas Health Science Center, 2007), and the Cleveland Clinic (Teacher of the Year Award, Department of Cardiovascular Medicine, 2011).
Dr. Chris J. Plummer, MD
Consultant Cardiologist, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Dr Plummer is a consultant cardiologist at the Freeman Hospital in Newcastle upon Tyne. His clinical work focuses on cardiac implantable electronic device therapies but he also has a major clinical and research interest in cardiovascular effects of cancer treatments. He has co-written cardio-oncology guidance in 3 areas, given advice on more than 50 clinical trials and co-founded the British Cardio-Oncology Society in 2014 where he is Secretary and wrote/published BC-OS.org.
Conference Topic: Session 9 - How and why to measure QT and what to do about it?Read More...
He trained in Bristol where he gained a PhD, St John's College Oxford where he completed his medical degree and in Newcastle where he undertook cardiology training. He is also involved in medical education from interviewing medical students to being the cardiology training programme director in the North East and serving on the exam board for the European General Cardiology Examination.
Dr. Ruth Plummer
Professor of Experimental Cancer Medicine, Northern Institute for Cancer Research, Newcastle University; Honorary Consultant Medical Oncologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Ruth Plummer is Professor of Experimental Cancer Medicine at the Northern Institute for Cancer Research, Newcastle University and an honorary consultant medical oncologist in Newcastle Hospitals Foundation Trust. She is Director of the Sir Bobby Robson Cancer Trials Research Centre, a dedicated clinical trials unit based within the regional cancer centre. She leads the Newcastle Experimental Cancer Medicine Centre and also the CRUK Newcastle Cancer Centre.
Co-Chair: Session 2 - Immunotherapy ad Emerging CardiotoxicityRead More...
She trained at Cambridge and Oxford before moving back home to Newcastle and settling with her family in the Tyne valley. Her clinical practice involves treating skin cancer, and a phase I all-comers practice, taking responsibility for one of the most active phase I unit’s in the UK. Her research interests are in the field of DNA repair and early phase clinical trials of novel agents, taking the first in class PARP inhibitor into the clinic in 2003, ATR inhibitor in 2012 and MCT1 inhibitor in 2014. Nationally she chairs the Cancer Research UK New Agents Committee, and sits as a member of Cancer Research UK’s Science Committee and Clinical Research Committee.
Dr. Sanjay Prasad
Consultant Cardiologist, Royal Brompton Hospital; Reader, National Heart and Lung Institute, Imperial College, London, United Kingdom
Dr. Sanjay Prasad is a consultant cardiologist at the Royal Brompton Hospital and Reader at the National Heart and Lung Institute, Imperial College, London. His areas of clinical interest include Cardiomyopathy and heart failure. In addition to his clinical work, he leads a research programme focused on clinical outcomes in risk stratification by CMR with a particular focus on the detection and significance of myocardial fibrosis.
Co-Chair: Day 1 Plenary Lecture
Prof. John Radford
Professor of Medical Oncology and Director of Research, The Christie Hospital; Molecular & Clinical Cancer Sciences University of Manchester, Manchester, United Kingdom
John Radford is Professor of Medical Oncology and Director of Research at The Christie Hospital, Manchester. Research interests are focused on developing and testing new ways of treating lymphoma and monitoring the effectiveness of these treatments using novel biomarkers, studying late effects of chemotherapy on fertility, heart function and the risk of second cancers and investigating how best to prevent or minimise the impact of these in people cured of lymphoma.
Conference Topic: Plenary Lecture - Long-term cardiovascular outcomes in survivors of Hodgkin's LymphomaRead More...
John is chair of the UK National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group, a member NCRI Hodgkin Lymphoma sub-group and chief investigator for many national and international trials.
Prof. Simon Ray
Honorary Professor of Cardiology, The University of Manchester, Manchester, United Kingdom
Simon Ray graduated in Pharmacology (1980) and Medicine (1983) from Bristol University. After early training in general medicine he completed an MD as a BHF funded research fellow with Professor Henry Dargie in Glasgow and then undertook specialist cardiology training in Newcastle, Liverpool and Vancouver. He was appointed consultant cardiologist at the University Hospitals of South Manchester in 1995 and Honorary Professor of Cardiology at the University of Manchester in 2011.
Co-Chair: Session 5 - Coordinating Primary Care in Cardio-OncologyRead More...
He has served as the President of the British Society of Echocardiography, Vice-President for Clinical Standards of the British Cardiovascular Society and President of the British Heart Valve Society.
Dr. Stuart D Rosen, MA, MD, FRCP, FESC, FACC, FHFA
Consultant Cardiologist, Royal Brompton and London Northwest Healthcare Hospitals; Reader in Cardiology, National Heart and Lung Institute, Imperial College London; United Kingdom. Treasurer of the British Cardio-Oncology Society.
Dr. Stuart Rosen is Consultant Cardiologist, Royal Brompton and London Northwest Healthcare Hospitals and Reader in Cardiology, National Heart and Lung Institute, Imperial College London; United Kingdom. He received his medical undergraduate education at Pembroke College, Cambridge and at Charing Cross and Westminster Medical School. His specialist cardiology training was at Charing Cross, Hammersmith and St Mary’s Hospitals.
Conference Topic: Session 3 - Cardiac outcomes of ADT in prostate cancerRead More...
In clinical practice, Dr Rosen is a general adult cardiologist and has specialist expertise in heart failure, syncope and hypertension. His technical skills include transoesophageal echocardiography, stress echo, tilt testing and autonomic assessment, as well as ultrafiltration for decompensated heart failure. Dr Rosen had a pivotal role in setting up the UK’s first cardio-oncology unit, at the Royal Brompton Hospital, to provide bespoke care for patients at risk of cardiotoxicity or who have developed cardiac problems as a consequence of their anti-cancer treatment. He is Founding Treasurer of the British Cardio-Oncology Society. Dr Rosen has a programme of translational research focused on: Role of cardiac autonomic dysfunction in pathophysiology of cardiac disease; Origins of cardiac pain [member of an international task force on complex cardiac pain syndromes]; Mechanisms of heart injury in cancer patients. He is also cardiologist to the MRC’s Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial, a multi centre study of cardiovascular outcomes in prostate cancer patients treated with transcutaneous oestrogen patches compared with LHRH analogues. Dr Rosen has a busy managerial role as Clinical Director of Medicine at LNW Hospitals. He also has extensive teaching commitments, in medicine, cardiology, ethics and law for medical undergraduates and supervises postgraduates, MD and PhD students. Dr Rosen is author of more than 70 peer reviewed papers, plus review articles, editorials, abstracts, nine book chapters two books.
Dr. Douglas Sawyer, MD, PhD
Chief of Cardiac Services, Maine Medical Centre, Portland, ME, USA
Dr. Doug Sawyer trained in medicine and cardiology at Brigham and Women’s hospital, and served on faculty at Boston University where he was a member of the BU Amyloid program, and subsequently at Vanderbilt University where he helped to found the Cardio-Oncology and Amyloid Programs. Doug has been the Chief of Cardiac Services at Maine Medical Center in Portland Maine since 2014.
Conference Topic: Session 7 - Proteosomal inhibitors and cardiac complications
Dr. Christine Simmons, MD
Medical Oncologist, BC Cancer Agency Vancouver; Clinical Associate Professor, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Dr. Christine Simmons is a Medical Oncologist at the BCCA Vancouver and Clinical Associate Professor in the Department of Medicine at the University of British Columbia. She completed her residency training in Toronto, and completed a fellowship at Princess Margaret Hospital in Toronto. She also completed a Master’s in Clinical Epidemiology at University of Toronto. She is currently the Chair of Sarcoma Systemic Program for BCCA.
Co-Chair: Session 3 - Hormonal Therapies and Cardiovascular RiskRead More...
She is the former chair of the Locally Advanced Breast Cancer National Consensus group and still plays a key role in that organisation. Her academic interests span both teaching and research, and she has held several leadership roles in the Undergraduate Medical Program at UBC in the areas of clinical skills and oncology education. Her research interests are in the areas of health services research in breast cancer and sarcoma. She recently founded the Sarcoma Outcomes Unit at the BC Cancer Agency, and is Founder and Chair of the not‑for‑profit organisation, Women in Cancer.
Prof. Roderick Skinner, MB ChB, PhD, FRCPCH, DCH
Consultant in Paediatric and Adolescent Oncology/Bone Marrow Transplantation, Great North Children's Hospital, Royal Victoria Infirmary; Honorary Professor of Childhood Cancer, Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
Professor Rod Skinner has been a Consultant in Paediatric and Adolescent Oncology / BMT at the Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne since January 1996, and is an Honorary Professor of Childhood Cancer, Northern Institute of Cancer Research, Newcastle University. He qualified in Birmingham in 1983, trained initially in general paediatrics and then in paediatric haematology/oncology and BMT in Newcastle, with further BMT experience in the Pediatric BMT Program, Minneapolis, USA.
Co-Chair: Session 10 - How to deliver a successful cardio-oncology serviceRead More...
He was awarded a PhD by Newcastle University in 1995 for his research thesis into chemotherapy-induced nephrotoxicity in children with cancer. He is the clinical lead in Newcastle for paediatric haematology allogeneic haemopoietic stem cell transplantation, long-term follow-up (LTFU), and bone marrow failure, and has a busy practice in paediatric / adolescent leukaemia. His research interests include late adverse effects of childhood cancer treatment, especially nephrotoxicity, and LTFU of childhood cancer survivors. He has played a leading role in the development of evidence-based, internationally-harmonised LTFU surveillance guidelines. He is a member of the UK Children’s Cancer and Leukaemia Group, with leading roles in the Late Effects Group (current chair), Supportive Care Group (chair 2003-08) and BMT Group (chair 2008-2012). He was a National Clinical Advisor in the NHS National Cancer Survivorship Initiative (2008-2012). He was one of the three instigators and founding members in 2008 of PanCare (Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer), and remains on its Executive Board.
Prof. Ian E. Smith, MD, FRCP, FRCPE
Professor of Cancer Medicine, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
Ian E. Smith, MD, FRCP, FRCPE, is Professor of Cancer Medicine at The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom. His initial medical training was in Edinburgh and then he came to the Royal Marsden, London, for specialist training in cancer medicine. He also spent some time in Boston at the Dana-Farber Cancer Institute, Harvard.
Conference Topic: Plenary Lecture - HER2 targeted therapies for breast cancer: New insights and cardiac safetyRead More...
Over the years his principal clinical research interests have been in breast cancer, lung cancer, and in new drug development. He was involved in the early clinical development of several anticancer drugs that have subsequently proved effective in the clinic, including carboplatin and letrozole. In the last decade he has become increasingly involved in neoadjuvant (preoperative) therapies as a research approach towards individualised treatments for breast cancer. He is currently Chief Investigator or UK Principal Investigator for several international multicentre breast cancer trials involving in particular targeted therapies and aromatase inhibitors. He publishes and lectures extensively. He was awarded the Susan G Komen for the Cure Brinker Award for Scientific Distinction at the 2009 San Antonio International Breast Cancer Conference. Professor Smith was appointed first chairman of the UK Breast Trials Intergroup and chairman of the British Breast Group. He was the Scientific Chairman of the Breast Section of 2012 ESMO, and he has also chaired several national professional bodies including the Association of Cancer Physicians, the Royal College of Physicians Specialist Advisory Committee for Medical Oncology, and the NCRI Lung Cancer Clinical Studies Group. He is was recently Co –Chairman of the ASCO Clinical Guidelines Group for Chemotherapy in Metastatic Breast Cancer, and has just been appointed the first Chair of the newly formed UK Breast Cancer Clinical Reference Group. He is a patron of Breast Cancer Care, the largest UK breast charity for patient support, and a Trustee of Breast Cancer Haven, another major patient support charity.
Dr. Susannah Stanway, MBChB, MRCP, MD, MSc
GCOS 2017 Co-Chair; Consultant in Medical Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Dr Susannah Stanway is a Consultant in Medical Oncology at The Royal Marsden NHS Foundation Trust. Having qualified from Bristol University in 1998, she obtained an MD thesis for her work on Steroid Sulphatase Inhibition in postmenopausal patients with Breast Cancer from Imperial College in 2009; her oncology training was undertaken at UCLH and The Royal Marsden NHS Foundation Trust.
Co-Chair: Day 2 Plenary Lecture - The Global Epidemic of Cancer and Cardiovascular DiseaseRead More...
She has been working at consultant level since 2012, both in the Acute Oncology Service at Croydon University Hospital and in the Royal Marsden NHS Foundation Trust’s Breast Unit. Along with actively recruiting patients to the large portfolio of research studies in the Breast Unit, her research interest is predominantly focused on Cancer Survivorship. This includes the area of cardio-oncology, in collaboration with amongst others, the Cardio-Oncology Group at the Royal Brompton Hospital and the London School of Hygiene and Tropical Medicine; treatment-induced Hot Flushes, where she sits on the NCRI Symptom Management Working Group; sexual and psychological consequences of cancer and has completed an MSc thesis on Risk Stratification to Guide Follow up after Childhood Malignancy. She co-chairs the Royal Marsden NHS Foundation Trust’s Living With and Beyond Cancer Committee; sits on the Royal Marsden Partners Survivorship pathway and has set up a pan-London multi-disciplinary survivorship research group; she leads the Living with and Beyond Cancer Module on the Institute of Cancer Research (ICR) MSc course; and has been actively involved with the Royal Marsden NHS Foundation Trust’s Young Women’s Breast Cancer Program since its inception; She has a personal interest in cancer control in low-middle income countries and she sits on the editorial board of ASCO’s Journal of Global Oncology, leads a sub-module on Cancer in Low-Middle Income Countries on the ICR MSc course and actively contributes to oncology education in East Africa with the Royal College of Physicians. She is immediate past president of the Oncology Section at the Royal Society of Medicine.
Prof. Justin Stebbing, MA FRCP FRCPath PhD
Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Foundation Trust, London, United Kingdom
Professor Justin Stebbing specialises in a range of malignancies, their treatment with immunotherapy (breast, GI and lung and clinical trials), having originally trained in medicine at Trinity College Oxford, where he gained a first class degree. After completion of junior doctor posts in Oxford, he undertook training and a residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew's Hospitals.
Co-Chair: Session 8 - New Scientific Advances in Cardio-OncologyRead More...
Professor Stebbing’s original PhD research investigated the interplay between the immune system and cancer; he was appointed a senior lecturer in 2007, and a Professor in 2009. Professor Stebbing has published over 600 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing regularly for national newspapers and presenting new data on optimal cancer therapies at the major international conferences. His focus at Imperial is on new therapies in cancer, and the systemic management of patients with solid malignancies including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells and cell free DNA. His laboratory work is concentrated on new druggable target discovery and gene regulation examining the role of non-coding RNAs in stem cells. The charity Action Against Cancer www.aacancer.org has been set up to support Justin's work which concentrates on drug development and has the ambitious goal of developing cures. He is a Fellow of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of a number of international cancer committees. He chairs the World Vaccine Congress and the Irish Cancer Society oversight committee and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and the Lancet Oncology; he was awarded the Silvia Lawler prize in 2015. Recently, Justin's team published in Nature Medicine the discovery of a new cancer-causing gene which we have now implicated in breast, gastro-intestinal, lung and other solid tumours. The National Institute for Health Research (NIHR) awarded Justin Stebbing its first translational research professorship in oncology, aiming to bridge the gap between the laboratory and the patient to ensure therapy is personalised. The focus of this is understanding why some patients with cancer relapse, and developing a program to reverse this and prevent it. With the excellent research record we have at Imperial College London and the clinical expertise from Imperial College Healthcare NHS Trust, we believe we are ideally placed to achieve this. He has an extensive clinical practice and links this to a wide number of translational research studies and immunotherapy trials including recent biosimilar studies. In 2016 Justin was internationally recognised with his appointment as Editor-in-Chief of Oncogene (Springer Nature's foremost cancer journal) and election to the American Society for Clinical Investigation. He has published papers on molecular mechanisms of cardiac toxicity including the role of non-coding RNAs in the gene regulation that occurs and sits on the European Society of Cardiology Committee for Practice Guidelines and has been involved in the task force for cancer treatments and cardiovascular toxicity.
Mr. Richard Stephens
Richard Stephens is a survivor of two cancers and a heart condition. He has participated in four clinical trials and nine other studies. After successful careers in local government and education, he is now a full-time voluntary patient advocate.
Conference Topic: Session 1 - Patient's PerspectiveRead More...
He was the patient representative on the Independent Cancer Taskforce that produced the English national cancer strategy, and as Chair of the National Cancer Research Institute’s Consumer Forum he leads a group of over 90 patients and carers involved in all aspects of cancer research throughout the UK. He works with policy-makers in the UK and in Europe, and currently serves on strategic groups at Genomics England, Cancer Research UK, EORTC, NIHR, MHRA, MRC, HRA and ABPI. In his spare time he studies acronyms.
Dr. Martin Štěrba, PharmD, PhD
Associate Professor and Deputy Head, Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czechia
Current Position - Associate Professor and Deputy Head, Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic. Head of the laboratory for in vivo study of cardiotoxicity of anticancer drugs. Education – MSc/PharmD in Pharmacy at Faculty of Pharmacy, Charles University (2002), PhD. in Medical Pharmacology at Faculty of Medicine in Hradec Kralove, Charles University (2007). Research focus – anticancer drug-induced cardiac dysfunction: molecular mechanisms and new opportunities for cardioprotection.
Conference Topic: Session 8 - Novel insights into mechanisms of dexrazoxane-mediated cardioprotection
Prof. Richard Sullivan
Director, Institute of Cancer Policy & Global Health, King's College London, London, United Kingdom
Richard Sullivan is Professor of Cancer & Global Health at Kings College London (KCL), Director, Institute of Cancer Policy and Co-Director of King’s Conflict & Health Research Group. Richard serves on the executive boards of King’s Health Partners Comprehensive Cancer Centre, the Kings’ Centre for Global Health and the Union for International Cancer Control. He also holds Visiting Chairs at the Universidad Catolica, Santiago and Tata Memorial Centre, Mumbai and is an elected Fellow of the European Academy of Cancer Sciences.
Conference Topic: Plenary Lecture - The Global Epidemic of Cancer and Cardiovascular DiseaseRead More...
Richard is past UK Director of the Council for Emerging National Security Affairs (CENSA) a national security think-tank where he specialised in counter-proliferation and the security implications of global health. Richard qualified in medicine, and trained in surgery (urology) gaining his PhD in cell signalling from University College London. He was clinical director of Cancer Research UK between 1999 and 2008. Following a period at the London School of Economics working on complex healthcare systems he moved to King’s College London in 2011. Richard’s research programmes focus on global cancer policy and conflict & health. In cancer public policy he has worked on a range of global policy research programmes, most recently Lancet Commission on Global Surgery 2030, Lancet Series on Women’s Equity, Health and Cancer and the Lancet Oncology Commission on Global Cancer Surgery. The King’s Conflict & Research Group is also carrying out a Lancet Commission into Civil-Military co-operation in Global Health, in addition to a wide variety of field studies including: basic package of health services in Afghanistan, armed violence reduction as public health measure, intelligence, security and global health, and health intelligence in the Syrian conflict. Richard has worked extensively in many conflict regions from the Balkans through to Afghanistan, Libya, Syria and DR Congo in both healthcare systems reconstruction and cancer control. In global ageing the Institute of Cancer Policy is working on the demographic impact of ageing middle income countries such as Mexico on cancer care and research systems, as well as cancer surgical issues germane to ageing population. The Conflict and Health Group is also involved in a study of the elderly refugee population and cancer care models.
Prof. Thomas Suter, MD
Professor of Medicine, University Hospital Bern, Bern, Switzerland
Dr. Karen L. Syrjala, PhD
Co-Director of Survivorship Program, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA
At the Fred Hutchinson Cancer Research Center, Dr. Syrjala is a Member and Director of Biobehavioral Sciences, and Co-Director of the Survivorship Program. At the University of Washington School of Medicine she is a Professor in the Department of Psychiatry and Behavioral Sciences. She is an Associate Editor for the Journal of Cancer Survivorship and has been on numerous journal editorial boards.
Conference Topic: Plenary Lecture - e-Health and cardio-oncologyRead More...
Among other national responsibilities, she has been on invited national panels to develop cancer-related guidelines, including for survivorship, pain, and symptom management. Her research is focused on examining long term outcomes and interventions to improve those outcomes for cancer survivors, including after hematopoietic cell transplantation and for young adults. In prospective longitudinal studies, she has examined neurocognitive recovery, musculoskeletal, sexual, emotional and physical function trajectories, and health care adherence in survivors. Recent studies are looking at online, social media and integrated technology methods for individualizing programs to meet survivor health needs, with a focus on cardiometabolic and subsequent malignancy health care adherence and management of emotional needs. She also is leading mouse to human studies targeting the mechanisms for late complications in cancer survivors. She mentors numerous junior faculty and fellows in cancer research across disciplines, and provides clinical services to oncology patients at the Seattle Cancer Care Alliance.
Dr. Sebastian Szmit, MD, PhD
Assistant Professor of Medicine; Cardiologist & Specialist of Internal Medicine, Centre of Postgraduate Medical Education, Otwock, Warsaw, Poland
Sebastian Szmit graduated from the Military Medical Academy in Poland, worked as an internal medicine doctor in the Military Institute of Medicine (2003-2012) and the Medical University of Warsaw (2007-2012). From 2012, he is a Cardio-Oncology Consultant and Chief of the Laboratory of Cardio-Pulmonary Exercise Testing in the Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education at the European Health Centre in Otwock.
Judge: Session 6 - Young Investigator CompetitionRead More...
Sebastian Szmit is the tutor of two PhD projects: (1)Comprehensive geriatric and cardio-oncological assessment as predictive and prognostic factors in selected cancer patients aged 65 years or older; (2) Prognostic value of selected cardiac echocardiographic parameters in patients receiving cardiotoxic anticancer therapy. Sebastian Szmit is the member of the Polish Cardiac Society & European Society of Cardiology (ESC). He was appointed the executive editor of the Task Force of National Consultants in Cardiology and Clinical Oncology, to develop the first two Polish documents of Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer (in 2010) and lung cancer (in 2012). He was invited as the reviewer for 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. -Author and Lecturer of the Specialized Course entitled "Oncology in Cardiology" in Centre of Postgraduate Medical Education in Poland. -Editor-in-Chief of OnCOReview - the Official Journal of East European Branch of the International Cardio-Oncology Society. -Research Coordinator in Cardio-Oncology Section of the Polish Lymphoma Research Group. -Clinical Lead for Onco-Cardiology Team of the Polish National Oncology Network.
Prof. Carlo Gabriele Tocchetti, MD, PhD
Associate Professor of Medicine, Federico II University, Naples, Italy
Prof. Carlo Gabriele Tocchetti got his MD in 1997, his Board in Cardiology in 2001 and his PhD in 2007 at Federico II University, Naples, Italy, and is currently Associate Professor of Medicine in the Department of Translational Medical Sciences, Federico II University, Naples, Italy since 2014, where he coordinates the Heart Failure outpatient unit, with a particular interest on HF due to antineoplastic therapies.
Co-Chair: Session 8 - New Scientific Advances in Cardio-OncologyRead More...
His cardio-oncologic interest developed in 2009 when he was a postdoctoral research fellow at Johns Hopkins University, Baltimore, MD, in the lab directed by Nazareno Paolocci, MD, PhD, and started collaborating with Kathy Gabrielson, PhD, dissecting the role of ErbB2 in the myocardium. These studies have been finally published on Cardiovasc Res, 2016. His previous studies and ongoing collaborations with Drs Kass and Paolocci in Baltimore have helped dissecting the cardiac contractile effects of HNO and the development of a novel HNO donor for treating human heart failure currently used in clinical trials. Back in Italy in 2010, Prof. Tocchetti established himself as a cardio-oncologic basic and clinical investigator, as witnessed by many publications on the topic as corresponding author. Prof. Tocchetti is also member of the Study Group on Cardio-Oncology of the Heart Failure Association of the ESC, and is Chair of the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). The main goal of his lab is to explore pathophysiologic mechanisms and therapeutic targets in cardiac dysfunction, with a particular interest on post-ischemic HF, genetic and inflammatory cardiomyopathies, Pulmonary Hypertension and RV dysfunction, and HF due to antineoplastic therapies, including novel anticancer immunotherapies and biologic drugs employed in inflammatory diseases.
Dr. Sean A. Virani, MD, MSc, MPH, FRCPC, FCCS
Associate Professor of Medicine, University of British Columbia; Provincial Heart Failure Lead, Cardiac Services BC, Vancouver, BC, Canada
Dr. Virani is a key opinion leader for heart failure in Canada. He is founding Director of the Heart Failure and Cardio-Oncology Programs at Vancouver General Hospital, Regional Director of Heart Failure Services for Vancouver Coastal Health/Providence Health Care, Heart Failure Physician Lead and Senior Medical Advisor at Cardiac Services BC, President of the Canadian Heart Failure Society as well as Associate Professor of Medicine at the University of British Columbia.
Co-Chair: Plenary Lecture - The Global Epidemic of Cancer and Cardiovascular DiseaseRead More...
He completed his internal medicine and cardiology training at UBC before embarking on a sub-specialization in heart failure and cardiac transplantation at Stanford University. He also has a Master’s degree in Public Health from Columbia University with a focus on healthcare management. His professional interests include public policy related to health care delivery with specific reference to healthcare systems redesign and quality in the Canadian context. Dr. Virani has authored a number of papers on chronic and acute decompensated heart failure, is Co-Chair of the Canadian Guidelines on Cardio-Oncology and is a principal investigator on numerous research trials. He serves on the Provincial Advisory Committee for Cardiac Health, the Canadian Heart Failure Guidelines Committee and Co-Chairs British Columbia’s Specialist Services Committee.
Dr. Ashutosh Wechalekar, MB BS, MD, FRPC, FRCPath, DM
Senior Lecturer, Honorary Consultant Haematologist, University College London and Royal Free London NHS Foundation Trust, London, United Kingdom
Dr Wechalekar is a Reader in Medicine and Haematology at University College London/University College London Hospital/Royal Free Hospital, London, UK. After medical training in India, he completed his haematology training in the UK. His interest in plasma cell disorders started with a fellowship in myeloma at the Princess Margaret Hospital, Toronto. His clinical and research is focused on plasma cell disorders particularly AL amyloidosis and he is the haematology lead for AL amyloidosis.
Conference Topic: Session 7 - Modern advances in the treatment of cardiac amyloidRead More...
His research interests including the development of better risk stratification of the disease, reducing early cardiac mortality in AL, imaging, clonal biology and new treatment strategies in AL amyloidosis. He leads on a number of clinical trials in AL amyloidosis and myeloma at UCL and has published extensively in the respective areas.
Dr. Ronald Witteles, MD
Associate Professor of Cardiovascular Medicine, Internal Medicine Residency Program Director, Stanford University School of Medicine, Stanford, CA, USA
Ronald Witteles, M.D. (Associate Professor of Cardiovascular Medicine, Stanford University School of Medicine) is a graduate of The University of Chicago Pritzker School of Medicine, and completed his residency, chief residency, and fellowship training at Stanford University. He holds ABIM board certification in Internal Medicine, Cardiovascular Disease, and Advanced Heart Failure and Transplant Cardiology.
Conference Topic: Session 10 - How should we measure the quality of a cardio-oncology service?Read More...
Dr. Witteles serves as Program Director for Stanford University’s Internal Medicine residency training program, and in that role he directly supervises >125 Internal Medicine residents and oversees all of the fellowship training programs in the Department of Medicine. He was a founder of and is Co-Director of the Stanford Amyloid Center, one of the nation’s leading centers for the treatment/research of amyloidosis. Dr. Witteles leads the Cardio-Oncology program at Stanford, and has published extensively in both the fields of Cardio-Oncology and amyloidosis.
Dr. Jay Wright, MBCHB, MD, FRCP
Lead Clinician for Heart Failure and Cardiac Devices; Consultant Cardiologist, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, United Kingdom
Dr Wright completed early postgraduate training and MD research in Leeds, prior to moving to Liverpool for completion of his training. A keen interest in cardiac dysfunction and device therapy led to his appointment as one of the first device therapists in the UK in 2004. As service lead he has developed one of the largest single centre complex device services in Europe, combining both comprehensive implantation and extraction facilities.
Conference Topic: Session 9 - How to manage patients with cardiac pacemakers or defibrillators undergoing cancer surgery or thoracic radiotherapy?Read More...
Involvement with innovative therapies has put Dr Wright at the forefront of SICD development and autonomic modulation evaluation. More recently Dr Wright has developed an interest in the management of cardio-oncology patients particularly those with breast tumours. He is a present developing a strategic service plan for the Cheshire and Merseyside region.